Non-Small Cell Lung Cancer (NSCLC) Market Expected to Expand at a CAGR of 11.2% Through 2027

According to a recent research report published by MarkNtel Advisors, the Global Non-Small Cell Lung Cancer (NSCLC) Market is expecting around 11.2% CAGR during 2022-27. The exponentially rising prevalence of lung cancers, especially NSCLC, across different corners of the world, i.e., augmenting the demand for their effective diagnosis & treatments and instigating governments of various countries to invest substantially in the healthcare infrastructure, is the prime aspect driving the global market.

Moreover, the growing necessity to cater to the high unmet needs of patients, i.e., instigating biopharma firms to bring innovations in existing therapeutics & introduce novel drugs for lung cancer treatments, is further boosting the Global Non-Small Cell Lung Cancer (NSCLC) Market.

Besides, increasing awareness among people about the easy availability of several diagnoses & treatments through various government campaigns, advertisements, etc., are also fueling the patient pool for NSCLC globally and, in turn, positively influencing the market growth, further states the research report, “Global Non-Small Cell Lung Cancer (NSCLC) Market Analysis, 2022.”

“In case you missed it, we are currently revising our reports. Click on the below to get the most latest research data with forecasts for years 2024 to 2030, including market size, industry trends, and competitive analysis. It wouldn't take long for the team to deliver the most recent version of the report.”

Download Sample PDF Copy of this Report: - https://www.marknteladvisors.com/query/request-sample/non-small-cell-lung-cancer-market.html

Non-Small Cell Lung Cancer Market Segmentation:

• By Diagnosis(Blood & Urine Tests, Imaging, Biopsy, Sputum Cytology, Bronchoscopy)
• By Cancer Type(Squamous Cell Carcinoma (SCC), Large Cell Carcinoma (LCC), Adenocarcinoma)
• By Treatment(Surgery, Chemotherapy, Immunotherapy (Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors, CTLA-4 Inhibitor)), Radiation Therapy (External Beam Radiation Therapy, Brachytherapy (Internal Radiation Therapy)), Radiofrequency Ablation (RFA), Targeted Therapy)

High Efficacy of Immunotherapy Drugs to Boost the Global Market

Immunotherapy is likely to significantly contribute to the worldwide expansion of the Non-Small Cell Lung Cancer (NSCLC) Market during 2022-27. It owes principally to the increasing number of patients with NSCLC & their growing awareness about the benefits of immunotherapy drugs like enhanced efficacy & safety that strengthen & direct the immune system of the body to detect & kill the cancer cells effectively.

Immune checkpoint inhibitors turn the immune system on to target the cancer cells directly & attack potentially harmful agents in the body. The most extensively used immune checkpoint inhibitors in immunotherapy include PD-1, PD-L1, & Cytotoxic T Lymphocyte-Associated Antigen (CTLA-4).

• By End-User(Hospitals, Cancer Centers, Others (Ambulatory Surgery Centers, etc.))
• By Region(North America, South America, Europe, Middle East & Africa, Asia-Pacific)
• By Country (The US, Canada, Mexico, Brazil, the UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia)

With Massive Healthcare Expenditure, North America Dominates the Market

Geographically, North America holds the largest share in the Non-Small Cell Lung Cancer (NSCLC) Market, principally due to the massive healthcare expenditure by governments of different countries toward introducing novel NSCLC medications and procuring more diagnosis equipment & drugs to cater to the unmet needs of patients.

Since the US is witnessing a massive patient pool for NSCLC, the leading biopharma companies in the country are showcasing collaborations, mergers & acquisitions, and partnerships to expand their visibility & product portfolios. Hence, is is another prominent aspect projecting lucrative prospects for the North America Non-Small Cell Lung Cancer (NSCLC) Market through 2027.

Competitive Landscape

The major companies in the Non-Small Cell Lung Cancer (NSCLC) Market include Allergan (AbbVie), AstraZeneca PLC., Boehringer Ingelheim, Bristol Myers Squibb, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline PLC., F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer Inc., and Sanofi S.A.

Key Questions Answered in the Research Report

1. What are the current & future trends in the Global Non-Small Cell Lung Cancer (NSCLC) Market?
2. How has the industry been evolving in terms of geography & product adoption?
3. How has the competition been shaping across various countries, followed by their comparative factorial indexing?
4. What are the key growth drivers & challenges for the Global Non-Small Cell Lung Cancer (NSCLC) Market?
5. What are the customer orientation, purchase behavior, & expectations from the leading players in the Global Non-Small Cell Lung Cancer (NSCLC) Market?

Who We Are:

Our team entails professional analysts and researchers who intelligently utilize research techniques to procure detail-driven, unbiased, and reliable data encompassing the industry. We aim to nurture a result-oriented team to offer strategically-moving insights to our clients. 

Our fact-based reports allow the user to design their motives, funds, and strategies, with a higher focus on mitigating confusion and bringing forward a clear insight into the industry. It further allows the clients to identify the lucrative opportunities awaiting.

Insights offered by MarkNtel Advisors comprise in-depth information on regional & country-based trends emerging in the industry. The team studies & compiles the prospects, ensuring consistency in reports.

Our services are beyond offering research reports to the clients and further expand into addressing queries while incorporating with them for advice, development, & execution of strategies for exception growth.

Other Trending Reports:

• https://www.einpresswire.com/article/738579723/halal-food-market-hits-usd-2-545-9-billion-mark-in-2023-forecasts-show-usd-5-243-billion-by-2030
• https://uberant.com/article/2043213-alkoxylates-market-size-share-in-depth-insights-future-opportunity-top-companies/
• https://uberant.com/article/2043322-asia-pacific-predictive-twin-market-growth-rate-future-and-forecast-2025/
• https://uberant.com/article/2043210-south-east-asia-cloud-kitchen-market-2023-2028-size-demand-growth-forecast-markntel-/   

For Media Inquiries, Please Contact: 

Call: +1 628 895 8081 | +91 120 4278433

Email: sales@marknteladvisors.com

Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511 

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India